DFX Intelligence

Data Factory

VentureFirminstitutional vcexempt_reporting_adviser

Pappas Ventures

Venture Capital

Durham, NC

Pappas Capital is among the Top Healthcare Venture Capital Firms, focused on advancing biopharma, biotech, and medical technologies that improve patient outcomes.

This is the graph view. The full profile, with its team, deals and sources, is on Venture Capital.Open the full profile →

Search this name across graphsid dfx:vc:df760a5c-443b-4457-a6ae-b67d1974471c

Data as of Sep 17, 2026 (this record's last observation) from federal regulator filings, firm and issuer disclosures. Page built Sep 19, 2026, 12:03 PM UTC and rebuilt at most every 15 minutes.

Relationships: 131
Dated events: 19
On other graphs: 0
Observed: Sep 12, 2026 to Sep 17, 2026
58 observations

Across DFX

This entity has not been resolved onto another DFX graph by a shared identifier. A name match elsewhere would be a candidate, never an identity, and none is recorded.

Facts

fact = as filed or announced; derived = computed by DFX; estimate = a band, never a point

Funds: 12
Vintages: 2009 to 2024
Reported GAV: $187Mgross asset value on Form ADV; never dry powder
Funds with fundraising evidence: 0derived
Investments: 80
Portfolio companies: 80
Investments, 12m: 80
Partner-attributed: 0
People: 32
Investment professionals: 18derived
Co-investors: 0derived
LP relationships: 0
Stated sectors: biotech,agtechas stated by the firm
Stated geography: asia,canada,germany,global,united states
Latest Form D: Mar 14, 2022
Latest ADV filing: Mar 31, 2026
Website: ampappas.com

Funds

Fund	Vintage	Lifecycle	Form D sold	GAV
PV VI Ceo Fund, LP	2024	Early deployment	$0	$6.4M
Pappas Life Science Ventures VI, LP	2024	Early deployment	$0	$37.0M
Asia Innovation Ventures, LP	2021	Mature	$200M	$89.8M
A.M. Pappas Life Science Ventures V, LP	2017	Harvest	$85.8M	$18.9M
PV V Ceo Fund, LP	2017	Harvest	$7.0M	$1.7M
Chiesi Ventures, LP	2015	Harvest	n/a	$26.8M
PV IV Ceo Fund, LP	2009	Harvest	$3.9M	$279,144
A. M. Pappas Life Science Ventures II, LP	n/a	Wound down	n/a	$3.7M
A. M. Pappas Life Science Ventures IV, LP	n/a	Unknown	n/a	$6.3M
PV III Ceo Fund, LP	n/a	Wound down	n/a	$206,424
A. M. Pappas Life Science Ventures III, LP	n/a	Wound down	n/a	$3.1M
A. M. Pappas Strategic Equities Fund IV, LP	n/a	Wound down	n/a	$130,111

Investments

round size is never this investor's check

Company	State	Stage	Round size	Partner	Attribution	Observed
Achillion Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Aclara Biosciences	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Aer Therapeutics, Inc.	Nc	n/a	n/a	n/a	Unknown	Sep 16, 2026
Afferent Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Aktis Oncology, Inc.	Ma	n/a	n/a	n/a	Unknown	Sep 16, 2026
Allievex	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Amplyx Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Anthera Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Arena Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Argomed	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Athersys	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Balance Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Barosense	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Bayhill Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Bioatla	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Biosyntech	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Braincells	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Calyx Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cardiodx	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cenerx Biopharma	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cequent Pharmaceuticals	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cerexa	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Chimerix	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
Cognetix	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026
4D Molecular Therapeutics	n/a	n/a	n/a	n/a	Unknown	Sep 16, 2026

Co-investors

pairs come only from shared rounds and listings

Investor	Co-investor	Shared deals	Shared companies	Last observed	Strength
Pappas Ventures	Canaan Partners	3	3	Sep 16, 2026	Recurring
1st Course Capital Management, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
Mitsui & Co. Global Investment, Inc.	Pappas Ventures	1	1	Sep 16, 2026	One time
Boston Millennia Partners	Pappas Ventures	1	1	Sep 16, 2026	One time
RED Rock Ventures	Pappas Ventures	1	1	Sep 16, 2026	One time
Eudemian Ventures, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
Granite Growth Health Partners	Pappas Ventures	1	1	Sep 16, 2026	One time
Task Force X Capital Management, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
Omega Fund Management, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
Juvo Ventures, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
Presidio Partners Management, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
K1 Investment Management LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
Avalon Ventures Management, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
TOP Tier Capital Partners, LLC	Pappas Ventures	1	1	Sep 16, 2026	One time
Advent Life Sciences LLP	Pappas Ventures	1	1	Sep 16, 2026	One time

Relationships

showing 80 of 131

Invested in (80)

→ PlexigenCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Colucid PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ CuraSen Therapeutics, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ ReprogenesisCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Curzion PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Cyclerion TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Ebm SolutionsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Elitra PhramaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Emerald BioagricultureCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Enlaza Therapeutics, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Envisia TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ FlowcardiaCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ GentisCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Illuminoss MedicalCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Istari OncologyCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Kezar Life SciencesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Lead TherapeuticsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ LipoScience, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Liquidia TechnologiesCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Lumena PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Marina BiotechCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Milestone PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ MethylgeneCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Mirum Pharmaceuticals, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ NereusCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ OrphomedCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Panacos PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ Peninsula PharmaceuticalsCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ PlexxikonCompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
→ OnKure Therapeutics, Inc.CompanyPortfolio listing
Sep 16, 2026 to presentfactThe subject's own site
and 50 more

Dated events

16 bookkeeping events (roster, classification and holdings changes) folded below

Occurred
Jul 1, 2019
Person joined
Matthew a. Boyer joined Schedule A of Pappas Ventures as Chief Financial Officer
Form ADVobserved 7 days ago
Occurred
Mar 31, 2015
Person left
Eric W. Linsley (Managing Partner And Member) no longer on Schedule A of Pappas Ventures
Form ADVobserved 7 days ago
Occurred
Apr 2, 2012
Adviser's first ADV filing
Pappas Ventures first filed Form ADV (ERA, venture capital fund adviser exemption)
Form ADVobserved 7 days ago

Show 16 bookkeeping events

Occurred
Mar 27, 2024
PV VI Ceo Fund, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $6,425,726
Occurred
Mar 27, 2024
Pappas Life Science Ventures VI, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $36,952,396
Occurred
Mar 30, 2022
PV III Ceo Fund, LP no longer reported on Form ADV by Pappas Ventures
Occurred
Mar 30, 2022
A. M. Pappas Life Science Ventures III, LP no longer reported on Form ADV by Pappas Ventures
Occurred
Mar 30, 2022
Asia Innovation Ventures, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $99,463,941
Occurred
Mar 29, 2017
A. M. Pappas Life Science Ventures II, LP no longer reported on Form ADV by Pappas Ventures
Occurred
Mar 29, 2017
A.M. Pappas Life Science Ventures V, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $64,782,654
Occurred
Mar 29, 2017
PV V Ceo Fund, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $6,206,412
Occurred
Mar 31, 2015
Chiesi Ventures, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $63,388,857
Occurred
Mar 31, 2014
A. M. Pappas Strategic Equities Fund IV, LP no longer reported on Form ADV by Pappas Ventures
Occurred
Apr 2, 2012
PV III Ceo Fund, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $4,825,600
Occurred
Apr 2, 2012
A. M. Pappas Life Science Ventures II, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $19,822,237
Occurred
Apr 2, 2012
A. M. Pappas Life Science Ventures IV, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $83,905,235
Occurred
Apr 2, 2012
A. M. Pappas Life Science Ventures III, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $78,163,866
Occurred
Apr 2, 2012
A. M. Pappas Strategic Equities Fund IV, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $196,302
Occurred
Apr 2, 2012
PV IV Ceo Fund, LP first reported on Form ADV by Pappas Ventures (Venture Capital Fund), GAV $3,980,455

Who to call

the organisation, the role and the published line, with the filing or website that published it; revealed to signed-in accounts

The firm's published line

Revealable: 1 business phone (Form ADV), 1 website (Form ADV) · as of 2026-09-12

Who to call is the organisation, the person's role and the line they published themselves: a business phone, office address, website or profile link from Form ADV, Form 13F or their own website, with that source named on every value. The counts above are what a reveal returns; a personal email is rarely published, so most reveals are the firm's line. Never data bought from a provider, never anything personal. Reveals by plan

Provenance